Research in the area of fetal programming has focused on intrauterine growth restriction. Few studies have attempted to examine programming mechanisms that ultimately lead to lambs with a greater potential for postnatal growth. We previously demonstrated that treatment of ewes with GH at the time of breeding led to an increase in birth weight. Therefore, the objective of this study was to determine the effects of a single injection of sustained-release GH given during the periconceptional period on fetal growth and development and to determine if the GH axis would be altered in these offspring. Estrus was synchronized using 2 injections of PGF 2α ; at the time of the second injection, ewes assigned to treatment were also given an injection of sustained-release GH. A maternal jugular vein sample was taken weekly to analyze IGF-I as a proxy for GH to estimate the duration of the treatment effect. In ewes treated with GH, IGF-I increased (P < 0.05) by wk 1 and remained elevated until wk 4 postinjection. Lambs were weighed, crown-rump length and abdominal girth were determined, and a plasma sample was collected. In a subset of male lambs, liver, heart, and brain weights were obtained, as well as left and right ventricular wall thicknesses. On postnatal d 100, a subset of ewe lambs were weighed and challenged with an intravenous injection of GHRH. Lambs from treated ewes had increased (P < 0.05) birth weight and abdominal girth compared with control lambs; however, there was no difference in crown-rump length. Expression of GH receptor and IGF-I were increased (P < 0.05) in lambs gestated by GH-treated ewes compared with control ewes. The left ventricular wall was thinner (P < 0.05) from lambs in the GH-treated group compared with control lambs. On postnatal d 100, those ewe lambs born to ewes treated with GH continued to be heavier (P < 0.05) and had no IGF-I response to GHRH challenge. In conclusion, treating ewes with a single injection of GH appeared to alter fetal growth and development. Lambs born to ewes treated with GH were larger at birth and had altered organ development, which may indicate that early maternal GH treatment may lead to permanent changes in the developing fetus. The ewe lambs maintained their growth performance to at least 100 d of postnatal life and appeared to have an altered GH axis, as demonstrated by the altered response to GHRH.
INTRODUCTION
Fetal programming is described as any environmental insult or stimulus that occurs during the development of key organs or tissues and that results in physiological alterations of offspring (Godfrey and Barker, 2000; Armitage et al., 2004) . The majority of animal models developed to date investigate negative aspects of fetal programming, and only a few have tried to ameliorate the experimentally induced intrauterine growth restriction (IUGR), by giving GH or IGF in gestation (Harding et al., 1997; Bauer et al., 2003; Wallace et al., 2004 Wallace et al., , 2006 .
The results of studies conducted on the effects of GH treatment during follicular growth, breeding, early embryonic development, or all 3 indicate that altering the early embryonic environment may improve embryonic survival and lead to altered fetal development (Davis et al., 1990; Folch et al., 2001; Costine et al., 2005; Starbuck et al., 2006) . Administration of recombinant bovine ST to dairy cows at 100 DIM improved conception rates by 39% (Starbuck et al., 2006) . Similarly, Folch et al. (2001) found that treatment with porcine GH at the time of superovulation increased the number of transferable embryos and the number of lambs born to donor ewes, even though it has been shown that GH treatment throughout the estrous cycle does not increase ovulation rates (Davis et al., 1990) .
Recently, we reported that a single injection of sustained-release GH administered to ewes at breeding altered the uterine environment at d 7 of gestation and increased birth weight by 10% (Costine et al., 2005) . Therefore, our hypothesis herein was that a single injection of sustained-release GH would alter fetal organ development, specifically those organs associated with the GH axis, and would affect postnatal development. The objectives were to determine if GH given immediately before breeding would alter 1) fetal organ development and 2) postnatal growth and function of the GH axis.
MATERIALS AND METHODS
All procedures were approved by the West Virginia University Animal Care and Use Committee.
Animals
Ewes (n = 33), primarily of Rambouillet breeding, from the West Virginia University farm were used for the experiment, which was carried out over 3 breeding seasons. During the natural breeding season, estrus was synchronized by administering 20 mg of PGF 2α (Lutalyse, Pfizer, New York, NY) on d 0 and a second injection of PGF 2α on d 8. Ewes were randomly assigned to either a control group (n = 19) or a GH-treated group (n = 14). The GH-treated group received a single 500-mg injection of sustained-release recombinant bovine GH subcutaneously (Posilac, Monsanto, St. Louis, MO) at the same time as the second PGF 2α injection. This dose was previously reported to increase uterine luminal IGF-I on d 7 of gestation and to result in larger lambs at birth (Costine et al., 2005) . After the second injection of PGF 2α , ewes were penned with rams of known fertility. Two rams of Rambouillet breeding were used for the experiment, and all ewes were exposed to the same rams within a given year regardless of treatment. A jugular vein blood sample was collected weekly from control and treated ewes to measure total IGF-I in plasma. Blood (5 mL) was collected into ED-TA-containing vacuum tubes. Plasma was separated by centrifugation at 3,000 × g for 15 min at 4°C. Plasma IGF-I has been shown to serve as a reasonable proxy for GH action (Baumann, 1991) . Total IGF-I was measured to determine how long the sustained-release GH actively altered maternal physiology. At term, all lambs (n = 51) born alive were processed shortly after birth (average gestation was 145 d). Average litter size per ewe (1.54 ± 0.08) was not different (P = 0.66) between the control (1.58 ± 0.12) and GH-treated (1.50 ± 0.14) groups.
Lamb Data
Shortly after birth, and before nursing, all lambs (control n = 31, treated n = 20; male n = 25, female n = 26; Tables 1 and 2 ) from all 3 yr were weighed and measured for crown-rump length, abdominal girth, and crown width. In the second and third years, a blood sample (see above for details) was collected from all lambs to measure IGF-I at birth before nursing (control n = 16, treated n = 12; male n = 15, female n = 13; Tables 1 and 2). In addition, all males in the second and third years (n = 22) were killed with an intravenous overdose of sodium pentobarbital (1.5 g; Sigma Chemical Co., St. Louis, MO) to determine brain, heart, and liver weights. Whenever possible, a portion of the liver was snap-frozen in liquid nitrogen for further analysis of hepatic expression of GH receptor and IGF-I. The heart was removed and weighed before the ventricles were separated from the atria and fixed in 10% formalin. After fixation, the right and left ventricular wall thicknesses directly below the atria were determined using calipers. Female lambs were not killed during this study because they were needed for future breeding studies.
GHRH Challenge
To assess whether there were any long-term postnatal consequences of the treatment during gestation on the hypothalamic-hypophyseal-hepatic axis, we performed a GHRH challenge (Suttie et al., 1991) . Ewe lambs from the second and third years (n = 12; 6 control and 6 treated) were raised together within their given year under similar nutritional conditions and were fed silage and were supplemented with corn. Ewe lambs that remained on this portion of the study were not supplemented with milk replacer except for the 1 lamb that was included only in the birth data. Ram lambs were not used for this portion of the study because they were killed for tissue collection at birth. At 100 d of age, lambs were weighed and a blood sample (see above for details) was collected (0 min). The lambs were then subjected to a GHRH challenge (3 μg/kg of BW; GHRH factor-29, Sigma Chemical Company; Suttie et al., 1991) and blood was collected at 10, 20, 30, 45, 60, and 90 min after challenge.
IGF-I
The concentration of IGF-I in plasma was determined using a commercially available ELISA previously validated in our laboratory (Diagnostic Systems Laboratories Inc., Webster, TX; Costine et al., 2005) . Briefly, this assay used 2 antibodies in a sandwich-type immunoassay. Horseradish peroxidase is linked to the secondary antibody, and in the presence of tetramethylbenzidine (a substrate for horseradish peroxidase), the absorbance is directly proportional to the concentration of IGF-I. The assay sensitivity was 10 ng/mL; the intraassay CV was 5.4% and the interassay CV was 6.4%.
Gene Expression
Liver RNA was extracted using TRIzol as described by Costine et al. (2007) . This procedure included 2 back extractions against acid phenol:chloroform (5:1; pH 4.5; Ambion, Austin, TX), followed by 2 back extractions against phenol:chloroform:isoamyl alcohol (25:24:1; pH 6.6) to remove additional proteins, DNA, and lipids. The RNA was reconstituted in 40 μL of nuclease-free water and the concentration was determined spectrophotometrically at 260 nm. The quality of RNA was determined by the appearance of bands corresponding to 28S and 18S rRNA and a distribution of mRNA of high molecular weight on a 1.5% agarose gel with ethidium bromide.
Complementary DNA was synthesized from 2 μg of RNA that was reverse transcribed using random hexamers and Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI). Real-time reverse transcription-PCR (iCycler, Bio-Rad Laboratories, Hercules, CA) was used to measure the abundance of cDNA, as described previously by Costine et al. (2007) and modified from Pfaffl (2001) , using the actual efficiency of amplification of each gene product. Primers specific for GH receptor, IGF-I, and acidic ribosomal protein (which was used as a control gene) were designed using the San Diego Supercomputer Biology WorkBench (http://workbench.sdsc.edu/) and synthesized (Integrated Diagnostics System, Coralville, IA). Primers for GH receptor (forward CATGTCACTGGACA-GATGGG; reverse TGTTTTCACCAGCAGAGACG), IGF-I (forward GCCAAAACGGTCAAAGGTGA; reverse AGGCATAATTGGGGAGCTTT), and acid ribosomal protein (forward CAACCCAGCTCTGGA-GAAAC; reverse GTGAGGTCCTCCTTGGTGAA) were optimized (all reactions were annealed at 58.7°C) using a pooled RNA sample that was created by combining RNA from a subset of samples from both treatment groups. The efficiency of each primer set was determined using this pool before assaying any samples, and was used to standardize the target gene ratio. The efficiency of amplification was determined by raising 10 to the power of (−1/slope), for which the slope was obtained by plotting the log of the concentration of cDNA against the critical threshold values (Costine et al. 2007 ). Efficiencies for GH receptor, IGF-I, and acid ribosomal protein were 1.84, 1.85, and 1.94 (i.e., 92, 93, and 97% theoretical yield), respectively.
Each PCR reaction contained 25 μL of iQ SYBR Green Supermix (Bio-Rad Laboratories), 2 μL of cDNA diluted to 1:2, and 3 μL each of 5 μM forward and reverse primer and 17 μL of water to reach a final reaction volume of 50 μL. A single product per ampli- Indicates tissues collected only from male offspring in the third year of study.
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Relative expression as compared with a pooled sample. ], where E is efficiency and Ct is the critical threshold}.
Statistical Analyses
The effect of GH treatment to the dam during the periconceptional period on lamb birth weight, crownrump length, abdominal girth, crown width, and IGF-I concentration was analyzed by ANOVA using the GLM procedure (SAS Inst. Inc., Cary, NC). The model included treatment, single vs. multiple birth, year, sex of the lamb, and interactions between treatment and single vs. multiple births and between treatment and sex of the lamb. The effect of GH treatment of the dam during the periconceptional period on brain weight, heart weight, liver weight, right and left ventricular wall thicknesses, and hepatic expression of IGF-I and GH receptor was analyzed by ANOVA using the GLM procedure in SAS. Because these data were collected only from ram lambs, the model included treatment, single vs. multiple births, and year (yr 2 and 3 only). The effect of GH treatment of the dam on IGF-I concentrations throughout gestation and after GHRH challenge in ewe lambs was analyzed by repeated-measures ANOVA using the mixed models procedure in SAS, using an autoregressive covariance structure. The relationships among variables were determined by the correlation procedure of SAS. All data are expressed as mean ± SEM.
RESULTS
Maternal IGF-I concentration was increased (P < 0.05) by the first week after GH treatment. The concentration of IGF-I in maternal circulation remained elevated through wk 4 and was similar to concentrations in control ewes by the fifth week of gestation ( Figure  1 ).
Both BW (P = 0.04) and abdominal girth (P < 0.01) at birth were greater in the group of lambs born to ewes treated with GH compared with those born to control ewes (Table 1) . However, no difference in crown-rump length (48.5 ± 1.4 cm; P = 0.08) or crown width (8.8 ± 0.2 cm; P = 0.18) was detected.
The thickness of the left ventricular wall at birth was decreased (P = 0.02) in male lambs born to ewes treated with GH compared with male lambs born to control ewes (Table 1) . However, no difference (P = 0.33) in the thickness of the right ventricular wall was detected (Table 1) . No difference (P = 0.30) in heart weight at birth was detected between the control and GH groups (34.7 ± 2.1 g). Brain weights were also not different (50.4 ± 2.1 g; P = 0.88).
Relative expression of GH receptor was increased (P = 0.004) in liver tissue of newborn male lambs born to ewes treated with GH compared with control lambs (Table 1) . Similarly, there was an increase (P = 0.03) in hepatic IGF-I expression in the GH group compared with the control group (Table 1) . However, liver weight at birth was not different (P = 0.30) between control male lambs and male lambs born to ewes treated with GH at breeding (108.9 ± 5.1 g). Plasma IGF-I at birth was not different (P = 0.30) in lambs from either treatment group (290 ± 50 ng/mL). However, there was a positive correlation (r = 0.48; P < 0.05) between birth weight and IGF-I concentration. At birth, there was a main effect of sex on both birth weight (P = 0.004) and crown-rump length (P = 0.04; Table 2 ), but there was no interaction between sex and treatment.
On postnatal d 100, ewe lambs born to ewes treated with GH were still 10% heavier (P < 0.05) than those born to control ewes (Figure 2 ). Ewe lambs born to control dams exhibited an increase of approximately 75% in IGF-I in response to a GHRH challenge on d 100, whereas ewe lambs born to dams treated with GH had no IGF-I response when challenged with GHRH (P < 0.05; Figure 3 ).
DISCUSSION
Administering a single injection of sustained-release GH before breeding alters the fetal growth and development of lambs. Lambs born to ewes treated with GH at breeding were 10% heavier at birth compared with control lambs. The increase in birth weight of lambs born to ewes treated with GH in the current experiment is in agreement with results found previously, in which 500 mg of sustained-release GH given at the time of breeding increased lamb BW by 10% (Costine et al., 2005) , even though in the current experiment GH was given at the time of the second PGF 2α injection. In contrast, administration of 0.1 mg/kg of GH twice daily to the dam for 10 d or once daily for 27 d in late gestation did not affect fetal growth (Stelwagen et al., 1994; Harding et al., 1997) . The difference is most likely in the time of GH administration at the beginning of pregnancy. The slight difference in the timing of GH administration between that used by Costine et al. (2005) and that in the current work is likely inconsequential because the effect of the sustained-release GH appears to have lasted for at least 28 d and the magnitude of the increase in birth weight in the 2 experiments was similar.
Administration of GH daily at 0.2 mg/kg from d 35 to 55 had no effect on fetal weight by the end of treatment and did not affect fetal weight at d 135 of gestation (Wright et al., 2008) . We interpret this to mean that whatever programming effect GH treatment has during very early gestation, the window of opportunity to impart that program is no longer open by as early as d 35 of gestation. Wright et al. (2008) chose d 35 to 55 to administer GH because this is the period of gestation in which the placenta is producing GH. However, increases in maternal pituitary GH or peripheral IGF-I during the first 4 wk of gestation may be more critical to affecting the growth of the fetoplacental unit than the GH produced for 20 d by the endometrium during wk 5 to 8 of gestation. In the pig, the influence of GH on fetal growth appears to exist both early and late. Administration of porcine GH at a concentration of 18 mg/d (given as 6-mg injections 3 times/d) from d 10 to 27 of gestation tended to increase fetal weights, particularly in those fetuses in the smallest quartile for fetal weight within a litter (Rehfeldt et al., 2001 ). Administration of 2 mg/d of porcine GH from d 25 to 50 of gestation in the pig had no effect on birth weight, whereas treatment from d 25 to 100 resulted in a 16% increase in birth weight (Gatford et al., 2004) . These authors focused on the duration of GH treatment; however, without a group treated for 25 d late in gestation, it is impossible to determine whether the timing or duration of GH treatment was most important.
Several researchers have attempted to ameliorate the effects of IUGR by administering GH during the latter portion of fetal development, but to our knowledge, only the study by Costine et al. (2005;  from this laboratory) and the current experiment have included GH administered during the periconceptional period. For example, in an experiment conducted by Bauer et al. (2003) , IUGR was induced by placental embolization on d 110 to 116, which was followed by direct infusion of GH to the fetus at a rate of 3.5 mg/d late in gestation. Growth hormone infusion did not alter fetal weight, crown-rump length, chest girth, or fetal growth rate (Bauer et al., 2003) . Wallace et al. (2004) used the overnourished pregnant adolescent ewe model as a means of inducing fetal growth restriction and examined whether 0.14 mg/kg of GH administered daily to the dam in midgestation (i.e., d 35 to 80) might alter fetal development. In their study, GH treatment appeared to have no effect on either fetal weight or umbilical girth (Wallace et al., 2004) . Using the same overnourished adolescent ewe model, we administered GH to the dam late in gestation at a concentration of 0.14 mg/kg daily from d 95 to 125. At d 130, GH treatment appeared to increase fetal weight and girth in the growth-restricted group, making them equivalent to the control group. However, at birth, the effect of GH treatment was no longer observed, leading to the suggestion that GH treatment late in gestation elicits only a transient response, if any (Wallace et al., 2006 ).
In the current experiment, GH administration occurred immediately before breeding and appeared to remain active during the first quarter of gestation, as observed by an increase in maternal IGF-I. We have speculated that the observed increases in fetal weight and abdominal girth in the current study were a result of altered embryo growth, leading to altered placental development and function, which would allow for in- creased placental efficiency late in gestation. Costine et al. (2005) observed an increase in placental efficiency, as determined by fetal weight divided by chorioallantoic weight, in GH-treated ewes compared with control ewes. This early embryonic programming may be a result of an altered uterine environment, which has been observed with GH treatment at breeding (Costine et al., 2005) . In other early embryo studies, exogenous progesterone administered during embryonic development seemed to advance the uterine environment and increase fetal growth. Those embryos exposed to an altered uterine environment by early progesterone administration had a greater fetal mass and longer crown-rump length compared with control embryos (Kleemann et al., 1994) . Similarly, embryos that were cocultured with granulosa cells before being returned to the recipient female were 14% heavier by d 61 of gestation and 18% larger by d 125 compared with those that were cultured in media only and not exposed to granulosa cells (Sinclair et al., 1999) .
A positive correlation between placental efficiency and fetal IGF-I concentrations has previously been reported for ewes treated with sustained-release GH at breeding (Costine et al., 2005 ). In the current study, treatment with GH before breeding increased the hepatic mRNA expression of both IGF-I and GH receptor in ram lambs at birth. As in the neonate, IGF-I is the major growth factor responsible for fetal growth, but the main stimulator for IGF-I secretion in utero is nutrients, not GH (Oliver et al., 1996; Bloomfield et al., 2006) . The postnatal decline in GH concentration to that of an adult is accompanied by an increase in the expression of both GH receptor and IGF-I, which together lead to GH-regulated IGF-I secretion after birth (Breier et al., 1994; Fowden, 1995) .
Little information has been reported on the effects of GH administration during gestation on postnatal development in lambs and, more specifically, how the GH axis of these lambs may be altered. In the current experiment, plasma IGF-I concentrations immediately after birth were not different between the treated and control groups. These results are similar to those found by Stelwagen et al. (1994) , who reported that the concentration of IGF-I immediately after birth was not different between control lambs and those exposed for 27 d to GH late in gestation at a concentration of 0.1 mg/ kg of ewe BW. In an IUGR environment induced by placental embolization, daily GH treatment at 3.5 mg/ kg for 20 d was able to increase concentrations of IGF-I in fetal circulation of the IUGR fetuses, but only to control concentrations (Bauer et al., 2003) . Those data agree with hepatic expression data, in which 3.5 mg/d of GH treatment late in gestation increased hepatic GH receptor expression, but not IGF-I (Bloomfield et al., 2006) . The current experiment examined only hepatic expression in newborn ram lambs and cannot be directly compared with the work of Bloomfield et al. (2006) ; however, it is important to note that the observed increase in hepatic mRNA expression of GH receptor and IGF-I expression in the GH group may indicate an altered GH axis. Treatment with GH before breeding also seemed to alter the postnatal growth and development of ewe lambs. At d 100 after birth, ewe lambs born to ewes treated with GH were still 10% heavier than lambs born to control ewes. Ewe lambs born to GH-treated ewes also had no response to GHRH challenge compared with control lambs.
We determined ventricular wall thickness in the present experiment because, during fetal development, the heart can undergo adaptive changes to compensate for alterations in fetal physiology. The observed decrease in left ventricular wall thickness may indicate that during fetal development, those offspring gestated by dams treated with GH at breeding have reduced peripheral vascular resistance. In sheep, under normal uterine conditions, cardiomyocyte growth is primarily hyperplastic until differentiation in late gestation, with the majority of hypertrophic growth occurring only after birth (Burrell et al., 2003) . This pattern of development appears to change under induced conditions of IUGR. For example, when placental embolization was used to induce fetal growth restriction late in gestation, an increase in ventricular wall thickness and right ventricular cardiomyocyte protein-to-DNA ratio (i.e., cell size) was observed in growth-restricted fetuses compared with control fetuses at d 130 (Murotsuki et al., 1997) . With a similar model, growth restriction retarded growth of the left ventricle, as measured by a decreased proportion of binucleated cardiomyocytes (i.e., inhibited maturation) at d 130 of gestation (Bubb et al., 2007) . Offspring from dams that were nutritionally restricted to 50% of the control group from d 28 to 78 of gestation had increased ventricular weight per gram of fetal BW (Vonnahme et al., 2003) . A hypertrophic increase in the fetal ventricular wall has been suggested to result from an increase in ventricular afterload, which is indicative of an increase in mean arterial pressure (Samson et al., 2000; Vonnahme et al., 2003) . We suggest that the reduced left ventricular wall thickness observed in the current study is consistent with a decrease in mean arterial pressure in fetuses gestated in ewes treated with GH before breeding.
In conclusion, treatment of ewes with a single injection of sustained-release GH before breeding altered fetal growth and development. Lambs born to ewes treated with GH were larger, had a reduced ventricular wall thickness (which is indicative of a reduced mean arterial pressure), and had what appeared to be alterations in the GH axis. Affecting, or programming, the early embryo potentially alters fetal development throughout gestation. The placenta is responsible for supplying nutrients for proper growth; it influences mean arterial pressure, which affects cardiovascular development, and its efficiency may directly affect the GH axis. The current work may stimulate a new line of thinking when examining developmental programming of the conceptus and how it ultimately alters postnatal growth and development of the offspring.
